Patents by Inventor Inger Lautrup-Larsen

Inger Lautrup-Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protease-stabilized insulin analogues
    Patent number: 9260502
    Abstract: The present invention relates to novel insulin analogs comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogs; insulin preparations containing the insulin analogs of the invention; and, a method of treating diabetes mellitus using these insulin analogs.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: February 16, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Per Balschmidt, Svend Ludvigsen, Thomas Børglum Kjeldsen
  • Process for preparing FGF21 with low degree of O-glycosylation
    Patent number: 9120871
    Abstract: Expression of FGF21 in a S. cerevisiae pmt2 knock out strain reduces the O-glycosylation significantly and does not decrease the expression level. Expression in mkc7 knock out strain can decrease degradation of FGF21 and analogues thereof. Point mutations at position R17 and R36 can decrease degradation of FGF21 and analogues thereof when they are expressed in yeast.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: September 1, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Rita Slaaby, Inger Lautrup-Larsen
  • Protease resistant insulin analogues
    Patent number: 9018161
    Abstract: The present invention relates to novel insulin analogues exhibiting resistance towards protease, wherein at least two amino acids are substituted and/or deleted relative to the parent insulin molecule. A method for the preparation of such insulin analogues, insulin preparations containing the insulin analogues of the invention and a method of treating diabetes mellitus using these insulin analogues is also provided.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: April 28, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Svend Ludvigsen, Ulla Ribel-Madsen, Per Balschmidt, Per Nørgaard, Svend Havelund
  • Method for making polypeptides
    Patent number: 8815541
    Abstract: The invention provides an improved method for producing polypeptides with a C-terminal glycine in a yeast transformant being characterized in having a non functional KEX1 gene. The method is in particular well suited to produce polypeptides with an aromatic amino acid residue attached to the C-terminal glycine. The yeast strain may have further non-functional protease genes selected from PEP4, YPS1, MKCI, YPS3, YPS5, YPS6, YPS7, PRB1, STE13 and KEX2.
    Type: Grant
    Filed: November 25, 2010
    Date of Patent: August 26, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Asser Sloth Andersen, Inger Lautrup-Larsen, Per Noergaard
  • PROCESS FOR PREPARING FGF21 WITH LOW DEGREE OF O-GLYCOSYLATION
    Publication number: 20130005951
    Abstract: Expression of FGF21 in a S. cerevisiae pmt2 knock out strain reduces the O-glycosylation significantly and does not decrease the expression level. Expression in mkc7 knock out strain can decrease degradation of FGF21 and analogues thereof. Point mutations at position R17 and R36 can decrease degradation of FGF21 and analogues thereof when they are expressed in yeast.
    Type: Application
    Filed: January 20, 2011
    Publication date: January 3, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Rita Slaaby, Inger Lautrup-Larsen
  • METHOD FOR MAKING POLYPEPTIDES
    Publication number: 20120282653
    Abstract: The invention provides an improved method for producing polypeptides with a C-terminal glycine in a yeast transformant being characterized in having a non functional KEX1 gene. The method is in particular well suited to produce polypeptides with an aromatic amino acid residue attached to the C-terminal glycine. The yeast strain may have further non-functional protease genes selected from PEP4, YPS1, MKCI, YPS3, YPS5, YPS6, YPS7, PRB1, STE13 and KEX2.
    Type: Application
    Filed: November 25, 2010
    Publication date: November 8, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Asser Sloth Andersen, Inger Lautrup-Larsen, Per Noergaard
  • PROTEASE-STABILIZED INSULIN ANALOGUES
    Publication number: 20110092419
    Abstract: The present invention relates to novel insulin analogues comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogues; insulin preparations containing the insulin analogues of the invention; and, a method of treating diabetes mellitus using these insulin analogues.
    Type: Application
    Filed: March 19, 2009
    Publication date: April 21, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Per Balschmidt, Svend Ludvigsen, Thomas Børglum Kjeldsen
  • PROTEASE RESISTANT INSULIN ANALOGUES
    Publication number: 20100009898
    Abstract: The present invention relates to novel insulin analogues exhibiting resistance towards protease, wherein at least two amino acids are substituted and/or deleted relative to the parent insulin molecule. A method for the preparation of such insulin analogues, insulin preparations containing the insulin analogues of the invention and a method of treating diabetes mellitus using these insulin analogues is also provided.
    Type: Application
    Filed: September 20, 2007
    Publication date: January 14, 2010
    Inventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Svend Ludvigsen, Ulla Ribel-Madsen, Per Balschmidt, Per Norgaard, Svend Havelund